KR20180101861A - Composition comprising ginseng extract and method for preparation of ginseng extract with enhanced saponine extraction efficiency and composition comprising ginseng extract thereof - Google Patents
Composition comprising ginseng extract and method for preparation of ginseng extract with enhanced saponine extraction efficiency and composition comprising ginseng extract thereof Download PDFInfo
- Publication number
- KR20180101861A KR20180101861A KR1020170028354A KR20170028354A KR20180101861A KR 20180101861 A KR20180101861 A KR 20180101861A KR 1020170028354 A KR1020170028354 A KR 1020170028354A KR 20170028354 A KR20170028354 A KR 20170028354A KR 20180101861 A KR20180101861 A KR 20180101861A
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- powder
- composition
- ginseng extract
- extract
- Prior art date
Links
- 235000020710 ginseng extract Nutrition 0.000 title claims abstract description 79
- 238000000605 extraction Methods 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims description 84
- 238000002360 preparation method Methods 0.000 title description 4
- SYXUBXTYGFJFEH-UHFFFAOYSA-N oat triterpenoid saponin Chemical compound CNC1=CC=CC=C1C(=O)OC1C(C=O)(C)CC2C3(C(O3)CC3C4(CCC5C(C)(CO)C(OC6C(C(O)C(OC7C(C(O)C(O)C(CO)O7)O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CCC53C)C)C4(C)CC(O)C2(C)C1 SYXUBXTYGFJFEH-UHFFFAOYSA-N 0.000 title 1
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 33
- 239000002904 solvent Substances 0.000 claims abstract description 29
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 28
- 239000000839 emulsion Substances 0.000 claims abstract description 28
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims description 149
- 235000008434 ginseng Nutrition 0.000 claims description 146
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 144
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 144
- 235000002789 Panax ginseng Nutrition 0.000 claims description 31
- 235000013361 beverage Nutrition 0.000 claims description 29
- 241000208340 Araliaceae Species 0.000 claims description 20
- 238000004945 emulsification Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 238000000265 homogenisation Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000011812 mixed powder Substances 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims 1
- 229930182490 saponin Natural products 0.000 abstract description 89
- 150000007949 saponins Chemical class 0.000 abstract description 88
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 87
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 240000004371 Panax ginseng Species 0.000 description 129
- 235000017709 saponins Nutrition 0.000 description 88
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000002253 acid Substances 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 239000000828 canola oil Substances 0.000 description 11
- 235000019519 canola oil Nutrition 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000003672 processing method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 235000019463 artificial additive Nutrition 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- 239000008169 grapeseed oil Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 238000007602 hot air drying Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- -1 Example 1- 3 saponin Chemical class 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- LWZFANDGMFTDAV-WYDSMHRWSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-WYDSMHRWSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000006715 negative regulation of smooth muscle cell proliferation Effects 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/26—Homogenisation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/31—Mechanical treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 인삼 추출물에 관한 것으로, 특히 사포닌 추출효율이 개선된 인삼 추출물 제조방법 및 그에 따른 인삼 추출물에 관한 것이다.The present invention relates to a ginseng extract, and more particularly, to a ginseng extract having improved saponin extraction efficiency and a ginseng extract thereof.
인삼은 오갈피나무과 인삼속에 속하는 다년생 초본류로서, 한방에서는 그 뿌리를 인삼이라 하며 약용으로 사용한다. 최근 인삼이 건강식품으로서 각광을 받기 시작함에 따라 그 수요가 급증하고 있는바, 식품으로서의 기호적인 측면과 약효에 대한 과학적 입증을 위한 연구가 필요하다.Ginseng is a perennial herbaceous plant belonging to the ginseng root and ginseng, and its root is called ginseng in medicine. Recently, the demand for ginseng as a health food has been increasing rapidly, and it is necessary to study the scientific aspect of the food as a symbolic aspect and its effect.
인삼 성분에 대해서는 1854년 미국의 Garriques가 인삼으로부터 무정형의 배당체 혼합물을 분리하여 panaquion이라고 명명하면서 최초의 과학적인 연구가 시작되었다. 그러나 본격적으로 현대과학적인 연구가 시작된 것은 1960년대이며, 특히 중요한 연구 결과 중 하나는 소련의 Brekhman에 의해 그때까지의 연구결과를 총괄적으로 정리하여 볼 때 인삼의 유효성분으로서 사포닌(saponin) 성분의 효능에 관한 것이었다. 그 후, 사포닌 성분을 중심으로 많은 연구들이 수행되어 왔다(高麗人蔘, 1994, 韓國人蔘煙草硏究院).For the ginseng ingredient, the first scientific study began in 1854 when Garriques of America separated the amorphous glycoside mixture from ginseng and named it panaquion. However, one of the most important research results in the 1960s was the start of the modern scientific research. Brekhman of the Soviet Union summarized the results up to that time, and found that the efficacy of saponin as an active ingredient of ginseng . Since then, many studies have been carried out mainly on saponin components (Koryo ginseng, 1994, Korea Ginseng Research Institute).
고려인삼으로 대표되는 Panax속 식물은 북태평양 연안의 아시아 및 북아메리카 대륙에 거쳐 생육하는 다년생 초본으로 약 11 종이 알려져 있다. Panax속 식물에는 사포닌, 산당체, 및 단백질 등이 함유되어 있고, 다량 함유된 사포닌은 그 종류도 매우 다양하며, 인삼의 여러 가지 약리효능 발현에 관여하고 있다. 지금까지 약 29종 이상의 사포닌이 분리되어 있는데, 비당부의 구조적 특징에 따라 디올(diol)계, 트리올(triol)계 및 올레난(oleanane)계로 구분할 수 있다. Panax species, represented by Korean ginseng, are perennial herbs grown on the North Pacific coasts in Asia and North America. About 11 species are known. Panax spp. Contains saponin, acid sugar, and protein, and saponin in a large amount is very diverse, and is involved in the expression of various pharmacological effects of ginseng. More than 29 kinds of saponins have been isolated so far, and they can be classified into diol system, triol system and oleanane system according to the structural features of the non-sugar moiety.
사포닌의 약리작용에 대해서 많은 연구결과가 있으며, 대표적인 사포닌 중 진세노사이드 Rb1은 중추억제 및 정신안정 작용, 중추성 섭식 억제작용, 공격성 행동억제, 진통작용, 항경련작용, 부신피질 자극 호르몬 및 코티코스테론 분비 촉진작용, 항불안작용, 콜레스테롤 생합성 촉진작용, 고콜레스테롤과 중성지방 및 유리지방산의 저하작용 등의 약리작용이 보고되었다.There have been many researches on the pharmacological action of saponin. Among the typical saponins, ginsenoside Rb1 has been shown to inhibit the central inhibition and mental stability, central feeding inhibition, aggressive behavior suppression, analgesic action, anticonvulsive action, Pharmacological actions such as promoting the secretion of cosolone, anxiolytic action, promoting cholesterol biosynthesis, and lowering of high cholesterol, triglyceride and free fatty acid have been reported.
또 다른 대표적인 사포닌인 진세노사이드 Rd는 부신피질 자극 호르몬, 코티코스테론 분비 촉진작용, 신장사구체 비대 억제 등의 약리작용이 보고되었다.Another typical saponin, ginsenoside Rd, has been reported to have pharmacological actions such as corticosteroid stimulating hormone, corticosterone secretion promoting action, and renal glomerular hypertrophy inhibition.
또 다른 대표적인 사포닌인 진세노사이드 Rg1은 면역기능 증강작용, 혈소판 응집 억제, 항트롬빈, 선용활성화 작용, 기억 및 학습기능 증진작용, 항피로 작용, 항스트레스 작용, 항염증작용, 간세포 증식 및 DNA합성 촉진 등의 약리작용이 보고되었다.Another representative saponin, ginsenoside Rg1, has been shown to be effective in enhancing immune function, inhibiting platelet aggregation, inhibiting antithrombin, osteocalcin activation, memory and learning function, antipyretic action, antistress action, antiinflammatory action, hepatocyte proliferation and DNA synthesis And pharmacological actions such as promotion were reported.
또 다른 대표적인 사포닌인 진세노사이드 Rg2는 혈소판 응집억제, 항트롬빈, 선용활성화 작용, 기억감퇴 개선, 평활근세포 증식억제작용, 아세틸콜린 유도 카테콜아민 분비 억제 및 세포내 칼슘유입 억제작용 등의 약리작용이 보고되었다.Another representative saponin, ginsenoside Rg2, is known to exhibit pharmacological actions such as inhibition of platelet aggregation, antithrombin, acupuncture, memory deceleration, inhibition of smooth muscle cell proliferation, inhibition of acetylcholine-induced catecholamine secretion, .
또 다른 대표적인 사포닌인 진세노사이드 Rg3는 암세포 전이 억제작용, 혈소판 응집억제 및 항혈전 작용, 실험적 간 상해 억제작용, 혈관이완 작용, 항암제의 내성 억제작용 등의 약리작용이 보고되었다.Another typical saponin, ginsenoside Rg3, has been reported to have pharmacological actions such as inhibiting the cancer cell metastasis, platelet aggregation inhibition and anti-thrombotic action, experimental liver injury inhibiting action, vasodilating action, and anti-cancer drug resistance.
또 다른 대표적인 사포닌인 진세노사이드 Rh1은 실험적 간 상해 억제작용, 종양세포 분화 촉진, 혈소판 응집억제 및 선용활성화 작용 등의 약리작용이 보고되었다.Another typical saponin, ginsenoside Rh1, has been reported to have pharmacological effects such as experimental liver injury suppression, tumor cell differentiation promotion, platelet aggregation inhibition, and acupuncture activation.
또 다른 대표적인 사포닌인 진세노사이드 Rh2는 암세포 증식 억제작용, 암세포 재분화유도 촉진작용, 암세포 침윤 억제작용, 종양증식 억제작용, 항암제의 항암활성 증대작용 등의 약리작용이 보고되었다.Another typical saponin, ginsenoside Rh2, has been reported to inhibit the proliferation of cancer cells, induce cancer cell regeneration induction, inhibit cancer cell infiltration, inhibit tumor growth, and increase the anticancer activity of anticancer drugs.
한편, 인삼을 이용한 건강 음료의 제조방법은 인삼의 추출물 중 특정 성분만을 분리 추출하여 이용하는 방법이 대부분이었으며, 이러한 인삼 추출물을 포함하는 음료 제조 시, 불용성 고체성분인 인삼 분말의 침전 및 액상의 상분리에 의한 층분리 등으로 인해 장기간 안정한 상태를 유지하는 것이 어려운 실정이었다.Meanwhile, most of the methods for preparing health drinks using ginseng include extracting and extracting only specific components of ginseng extract. In the production of beverages containing such ginseng extract, the ginseng powder as an insoluble solid component and the phase separation of liquid phase It is difficult to maintain a stable state for a long period of time due to the separation of the layers due to the presence of the layer.
이에, 대한민국 등록특허 제10-0658772호와 같이 인삼의 초미세 분말화를 통해 인삼의 전체 성분을 섭취하면서도 음료의 안정성을 확보한 제품이 개발되었다.Thus, as disclosed in Korean Patent No. 10-0658772, a product obtained by ingesting whole ingredients of ginseng through ultrafine powdering of ginseng and securing stability of beverage has been developed.
그러나, 인삼 분말의 침전을 방지하기 위한 합성 안정제, 풍미를 증진하기 위해 사용된 유지성분의 유화안정성을 위한 합성 유화제 등의 합성 첨가물의 사용으로 인해 소비자들의 불안감이 증가하고 있는 상황이다.However, the use of synthetic additives such as synthetic stabilizers to prevent precipitation of ginseng powder and synthetic emulsifiers to stabilize the emulsification of the preservatives used to enhance the flavor have increased the anxiety of consumers.
최근 커피의 카제인나트륨과 인산염 이슈에서 민감한 반응을 보인 소비자들에서 알 수 있듯이 합성첨가물에 대한 소비자들의 부정적 인식은 향후에도 지속될 것으로 예상된다.Consumers' negative perception of synthetic additives is expected to continue in the future, as seen by consumers who have recently experienced a sensitive response to casein sodium and phosphate issues in coffee.
그러나, 천연 안정제 및 천연 유화제는 합성 안정제 및 합성 유화제에 비하여 유화력 및 분산안정성이 떨어져 음료 상품화에 적용되기 어려운 상황이다.However, natural stabilizers and natural emulsifiers are less emulsifying and dispersing stability than synthetic stabilizers and synthetic emulsifiers, and are difficult to apply to beverage commercialization.
따라서, 인삼 영양 성분을 섭취할 수 있으면서도, 합성 안정제와 합성 유화제를 실질적으로 포함하지 않는 인삼 음료 제조방법의 개발이 필요한 상황이다.Therefore, it is necessary to develop a ginseng beverage manufacturing method which can take the ginseng nutrition ingredient but does not substantially contain the synthetic stabilizer and the synthetic emulsifier.
이에 본 발명이 해결하고자 하는 과제는 상술한 문제를 해결하고, 인삼 추출물의 유효성분 함량을 개선하고, 유화 안정성이 개선된 인삼 추출물을 제조하는 방법, 이러한 방법에 따라 제조된 가공 인삼 추출물, 및 상기 인삼 추출물을 포함하는 조성물을 제공하기 위한 것이다.SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to solve the above-mentioned problems, to provide a ginseng extract having improved active ingredient content, improved emulsion stability, processed ginseng extract, And a composition comprising the ginseng extract.
상기 기술적 과제를 달성하기 위하여, 본 발명은 추출용매에 식용유지를 혼합하여 제조한 인삼 추출물을 제공한다. 구체적으로 하기 단계를 포함하는 인삼 추출물의 제조방법, 이러한 방법에 따라 제조된 인삼 추출물, 및 이러한 인삼 추출물을 포함하는 조성물을 제공한다.In order to accomplish the above object, the present invention provides a ginseng extract prepared by mixing edible oil in an extraction solvent. Specifically, the present invention provides a method for producing ginseng extract comprising the following steps, a ginseng extract prepared by the method, and a composition comprising the ginseng extract.
(a) 인삼분말, 용매, 및 식용유지를 혼합하는 단계;(a) mixing ginseng powder, a solvent, and an edible oil;
(b) 상기 혼합물을 이용해 인삼 추출물을 제조하는 단계.(b) preparing a ginseng extract using the mixture.
본 발명자들은 상기 단계를 포함해 인삼 추출물을 제조하면, 추출물 내 인삼 영양성분 특히, 사포닌, 산당체, 단백질의 함량이 증가할 뿐만 아니라, 인삼 추출물을 이용하여 음료 조성물 제조 시, 음료 조성물의 유화력 및 유화안정성이 현저하게 개선되는 것을 확인하여 본 발명을 완성하였다.The inventors of the present invention have found that when the ginseng extract is prepared, the content of ginseng nutrients, especially saponin, acid sugar and protein, in the extract is increased, and when the beverage composition is prepared using the ginseng extract, And the emulsion stability is remarkably improved, thereby completing the present invention.
일 실시예에서 인삼 추출물 내 사포닌 함량이 높을수록 유화력이 개선되고, 산당체 및 단백질의 함량이 증가할수록 유화안정성이 개선되는 것을 확인하였다. In one embodiment, the higher the saponin content in the ginseng extract was, the better the emulsifying power was, and the better the acid sugar and protein content, the better the emulsion stability.
본 발명의 명세서에 있어서, ‘인삼’은 학명 Panax schinseng NEES으로 두릅나무과의 다년생 초본 식물을 말하며, 생장환경, 생장기간, 또는 가공방법에 따라 인삼을 분류하는 명칭에 국한되지 않고, 상기 학명에 해당되는 것은 모두 본 발명에서 지칭하는 인삼에 포함된다. 예컨대, 수삼, 백삼, 홍삼, 산양삼, 산삼 또는 산삼배양근이 있으나, 이에 제한되지 않는다.In the context of the present invention, the "carrot" is the scientific name Panax schinseng NEES refers to perennial herbaceous plants of Araliaceae, and is not limited to the name for classifying ginseng according to the growth environment, growth period, or processing method, and all of the above names are included in the ginseng referred to in the present invention. For example, ginseng, white ginseng, red ginseng, goat ginseng, wild ginseng or wild ginseng culture root, but is not limited thereto.
각 단계별로 구체적으로 설명하면, 하기와 같다.Each step will be described in detail as follows.
(a) 인삼분말, 용매, 및 식용유지를 혼합하는 단계(a) mixing ginseng powder, a solvent, and an edible oil
상기 인삼분말을 준비하기 위해, 시판되는 인삼분말을 사용할 수 있으며, 또는 당업계에 공지된 방법으로 인삼분말을 제조하여 사용할 수 있다. 예컨대, 세척한 인삼을 1일 동안 태양 빛에 건조하고, 4등분으로 슬라이스 한 후, 분쇄기에 투입하여 인삼분말을 준비할 수 있으나, 이에 제한되는 것은 아니다.In order to prepare the ginseng powder, commercially available ginseng powder may be used, or ginseng powder may be prepared by a method known in the art. For example, the washed ginseng can be dried in sunlight for 1 day, sliced into quarters, and then introduced into a pulverizer to prepare ginseng powder, but the present invention is not limited thereto.
또한, 상기 인삼분말은 수삼분말, 백삼분말, 홍삼분말, 산양삼분말, 산삼분말 또는 흑삼분말 등을 사용할 수 있으며, 바람직하게는 백삼분말, 홍삼분말, 흑삼분말, 또는 이들의 혼합물을 사용할 수 있으며, 더 바람직하게는 백삼분말을 사용할 수 있으나, 이에 제한되는 것은 아니다.The ginseng powder may be selected from the group consisting of ginseng powder, white ginseng powder, red ginseng powder, ginseng ginseng powder, ginseng powder, and ginseng powder, and preferably white ginseng powder, red ginseng powder, More preferably white ginseng powder can be used, but is not limited thereto.
상기 용매는 인삼분말로부터 각종 성분을 추출하기 위한 추출용매로서 사용되는 것으로, 당업계에서 추출용매로 사용하는 것이라면 특별히 제한되지는 않으나, 물, C2-C4인 알코올, 또는 이들의 혼합용매를 사용할 수 있으며, 바람직하게는 물 또는 에탄올을 사용할 수 있고, 더 바람직하게는 물을 사용할 수 있다.The solvent is used as an extraction solvent for extracting various components from ginseng powder and is not particularly limited as long as it is used as an extraction solvent in the art. However, water, a C2-C4 alcohol, or a mixed solvent thereof can be used And preferably water or ethanol can be used, and more preferably water can be used.
일 실시예에서, 물을 용매로 하는 경우 제조된 인삼 추출물의 유화력이 가장 효과적으로 개선되는 것을 확인할 수 있었다.In one embodiment, it was confirmed that when water is used as a solvent, the emulsifying power of the manufactured ginseng extract is most effectively improved.
상기 식용유지는 당업계에서 사용할 수 있는 식용유지라면 제한되는 것은 아니며, 예를 들어 대두유, 카놀라유, 포도씨유, 올리브유, 옥배유, 아마인유, 미강유, 채종유, 땅콩유, 유채유, 옥수수유, 야자유, 카카오유, 팜핵유 등 식물성 유지 또는 이들의 혼합물을 사용할 수 있으며, 바람직하게는 대두유, 카놀라유, 포도씨유, 올리브유를 사용할 수 있으나, 이에 한정되는 것은 아니다.The edible oil is not limited as long as it is an edible oil which can be used in the art and includes, for example, soybean oil, canola oil, grape seed oil, olive oil, corn oil, linseed oil, rice bran oil, rapeseed oil, peanut oil, rape oil, corn oil, Vegetable oil such as palm kernel oil, and mixtures thereof. Preferably, soybean oil, canola oil, grape seed oil, and olive oil can be used, but the present invention is not limited thereto.
또한, 상기 식용유지는 식용유지:용매의 중량비가 1:1.5-25로 용매와 혼합할 수 있으며, 바람직하게는 1:2-20으로 혼합할 수 있다. 상기 식용유지가 용매와 1:1.5-25의 중량비로 혼합되는 경우 인삼 추출물 내 사포닌 함량을 효과적으로 개선할 수 있으며, 본 발명이 목적하는 유화력 및 유화안정성을 개선할 수 있는 인삼 추출물을 제공할 수 있다.In addition, the edible oil may be mixed with a solvent at a weight ratio of edible oil: solvent of 1: 1.5-25, preferably 1: 2-20. When the cooking oil is mixed with the solvent at a weight ratio of 1: 1.5-25, the saponin content in the ginseng extract can be effectively improved, and the ginseng extract of the present invention can improve the emulsifying power and emulsion stability desired.
일 실시예에서, 본 발명자들은 백삼분말을 사용하는 경우, 식용유지를 용매 총 중량 대비 10 중량% 혼합하는 경우, 사포닌 함량이 가장 높음을 확인하였다. 또한, 홍삼분말 또는 흑삼분말을 사용하는 경우, 식용유지를 용매 총 중량 대비 25-30 중량% 혼합하는 경우, 사포닌 함량이 가장 높음을 확인하였다.In one embodiment, the present inventors have found that when white ginseng powder is used, the highest saponin content is obtained when 10 wt% of the vegetable oil is mixed with the total weight of the solvent. In addition, when red ginseng powder or black ginseng powder was used, the highest content of saponin was confirmed when 25-30% by weight of the total weight of the edible oil was mixed with the solvent.
또한, 상기 인삼분말은 인삼분말:용매의 중량비가 1:5-15로 용매와 혼합할 수 있으며, 바람직하게는 1:8-12, 가장 바람직하게는 1:10으로 혼합할 수 있다. 상기 인삼분말이 용매와 1:5-15의 중량비로 혼합되는 경우 본 발명이 목적하는 유화력 및 유화안정성을 개선할 수 있는 인삼 추출물을 제공할 수 있다.The ginseng powder may be mixed with a solvent in a weight ratio of ginseng powder: solvent of 1: 5-15, preferably 1: 8-12, and most preferably 1:10. When the ginseng powder is mixed with the solvent at a weight ratio of 1: 5-15, the ginseng extract of the present invention can improve the emulsifying power and emulsion stability desired.
또한, 상기 인삼분말은 백삼분말과 홍삼분말을 혼합한 혼합분말을 사용할 수 있으며, 혼합분말을 사용하는 경우, 인삼 추출물 내 사포닌과 산당체 및 단백질 함량을 개선할 수 있다. 특히 상기 혼합분말 내 혼합 중량비는 백삼분말:홍삼분말로 95:5 내지 60:40, 바람직하게는 90:10 내지 70:30, 가장 바람직하게는 80:20으로 혼합할 수 있다. 상기 혼합 중량비를 95:5 내지 60:40으로 하는 경우, 인삼 추출물 내 사포닌의 함량 뿐만 아니라, 유화력과 유화 안정성이 현저하게 개선된 인삼 추출물을 제공할 수 있다.The ginseng powder may be a mixture of white ginseng powder and red ginseng powder, and when mixed powder is used, saponin, acid sugar and protein content in ginseng extract may be improved. Particularly, the mixing weight ratio of the mixed powder may be mixed with white ginseng powder: red ginseng powder at a ratio of 95: 5 to 60:40, preferably 90:10 to 70:30, and most preferably 80:20. When the mixing weight ratio is 95: 5 to 60:40, it is possible to provide a ginseng extract having remarkably improved emulsifying power and emulsion stability as well as the content of saponin in ginseng extract.
일 실시예에서, 본 발명자들은 유화상태는 유화력과 유화안정성으로 평가할 수 있으며, 사포닌 함량이 높은 경우 유화력이 개선되며, 사포닌 외 단백질 및 산당체의 함량이 높은 경우 유화안정성이 개선되는 것을 확인하였다.In one embodiment, the present inventors have found that the emulsified state can be evaluated by the emulsifying power and the emulsion stability, the emulsifying power is improved when the saponin content is high, and the emulsion stability is improved when the content of the saponin outer protein and the acid saccharide is high.
일 실시예에서, 백삼분말을 이용하여 인삼 추출물 제조 시, 단백질 및 산당체의 함량이 우수하고, 홍삼분말을 이용하여 인삼 추출물 제조 시, 사포닌의 함량이 우수함을 확인하였다.In one embodiment, the content of protein and acid sugar in the preparation of ginseng extract using white ginseng powder was excellent, and it was confirmed that the content of saponin was excellent when preparing ginseng extract using red ginseng powder.
(b) 상기 혼합물을 이용해 추출물을 제조하는 단계(b) preparing an extract using the mixture
본 단계에서 인삼분말 내 유효성분의 추출이 이루어지며, 상기 추출 단계는 통상의 기술자가 당업계에 공지된 다양한 방법을 선택할 수 있으며, 예컨대, 가열추출, 교반추출 등의 방법을 선택할 수 있다. 바람직하게는 고속 균질화의 방법을 이용할 수 있다.In this step, the active ingredient in the ginseng powder is extracted, and the extraction step can be carried out by various methods known to those skilled in the art. For example, the extraction method and the stirring extraction method can be selected. Preferably, a method of high-speed homogenization can be used.
본 발명에 따른 명세서에 있어서 ‘고속 균질화’는 반응물을 원심식 균질기(homogenizer), 또는 원심분리기 등을 이용하여 일정한 교반 속도로 교반하는 일련의 과정을 총칭하기 위해 사용한다. In the specification of the present invention, 'high-speed homogenization' is used to collectively describe a series of processes in which reactants are stirred at a constant stirring speed using a centrifugal homogenizer or a centrifugal separator.
상기 고속 균질화 단계는 구체적으로 하기의 단계들을 포함할 수 있다.The high-speed homogenization step may specifically include the following steps.
(b1) 5,000 내지 10,000 rpm인 일정한 속도에서 5 내지 40분 동안 교반하는 제 1 균질단계;(b1) a first homogenizing step at a constant speed of 5,000 to 10,000 rpm for 5 to 40 minutes;
(b2) 10,000 내지 15,000 rpm인 일정한 속도에서 5 내지 100분 동안 교반하는 제 2 균질단계.(b2) a second homogeneous step of stirring for 5 to 100 minutes at a constant rate of 10,000 to 15,000 rpm.
특히, 상기 제 2 균질단계 (b2)는 5 내지 60분 동안 교반할 수 있다.In particular, the second homogenization step (b2) may be stirred for 5 to 60 minutes.
일 실시예에서, 본 발명자들은 식용유지를 혼합하지 않고 물로만 인삼 추출물을 제조하는 경우와 비교하여, 식용유지를 혼합하여 특정 시간 교반하는 경우 인삼 추출물 내 사포닌 함량이 개선됨을 확인하였다.In one embodiment, the present inventors have found that the saponin content in the ginseng extract is improved when the edible oil is mixed and agitated for a certain period of time, as compared with the case where the ginseng extract is prepared only with water without mixing the edible oil.
상기의 고속 균질화 단계 후 (c) 상기 고속 균질화 후 상등액을 회수하는 단계를 더 포함할 수 있다.(C) recovering the supernatant after the high-speed homogenization.
상기 고속 균질화 후 분리된 상등액을 회수하여 인삼 추출물을 제공할 수 있다. 바람직하게는 상기 고속 균질화 후 분리된 침전물을 여과하여 (a)단계, (b)단계를 수회 반복, 바람직하게는 1-3회 반복한 후 분리된 상등액을 회수하여 인삼 추출물을 제공할 수 있다.The supernatant separated after the high-speed homogenization can be recovered to provide ginseng extract. Preferably, the precipitate separated after the high-speed homogenization is filtered to repeat the steps (a) and (b) several times, preferably 1-3 times, and the separated supernatant is recovered to provide the ginseng extract.
상기 인삼 추출물은 가공 분말 제조, 음료 조성물 제조, 또는 기타 식품 조성물 제조에 제공될 수 있으나, 이에 제한되는 것은 아니다.The ginseng extract may be provided for, but not limited to, preparing a processed powder, preparing a beverage composition, or producing other food compositions.
추가적으로, 본 발명의 제조방법은 (d) 인삼 추출물을 농축하는 단계를 더 포함할 수 있다. 본 공정을 통해, 고농축액 인삼 추출물을 제공할 수 있다.In addition, the process of the present invention may further comprise (d) concentrating the ginseng extract. Through this process, a highly concentrated ginseng extract can be provided.
또한, 상기 ‘농축’을 위한 방법으로 통상의 기술자가 당업계에 공지된 다양한 방법을 선택할 수 있으며, 예컨대 열풍으로 용매를 증발시키는 방법, 또는 동결건조의 방법 등을 선택할 수 있으나, 이에 제한되는 것은 아니다.As a method for the 'concentration', a variety of methods known in the art can be selected by a person skilled in the art. For example, a method of evaporating a solvent by hot air or a method of freeze drying may be selected. no.
본 발명에 따른 가공방법에 따르면, 유화력 및 유화안정성이 개선된 인삼 추출물을 제공할 수 있다. 인삼 추출물의 유화력 및 유화안정성은 인삼의 유효성분, 예컨대 사포닌, 단백질, 산당체 등의 함량에 의해 결정될 수 있으며, 특히 본 발명자들은 본 발명의 가공방법에 따라 인삼 추출물을 제조하는 경우, 본 발명이 아닌 가공방법으로 제조된 인삼 추출물의 사포닌 추출효율과 비교하여 사포닌 추출효율이 개선됨을 확인하였다.According to the processing method of the present invention, it is possible to provide a ginseng extract having improved emulsifying power and emulsion stability. The emulsifying power and emulsion stability of the ginseng extract can be determined by the content of active ingredients of ginseng such as saponin, protein, acid sugar, etc. In particular, when the ginseng extract is prepared according to the processing method of the present invention, Saponin extraction efficiency of ginseng extract prepared by non - processing method was improved.
본 발명의 일 양태에서, 본 발명자들은 건조된 백삼 원료의 사포닌 함량 (28.4-30.8 mg/g)과 비교하여, 본 발명에 따라 제조된 백삼 추출물의 사포닌 함량이 21.1-23.7 mg/g임을 확인하였다.In one aspect of the present invention, the present inventors confirmed that the saponin content of the white ginseng extract prepared according to the present invention is 21.1-23.7 mg / g as compared with the saponin content (28.4-30.8 mg / g) of the dried white ginseng material .
본 발명의 일 양태에서, 추출효율을 {(인삼 추출물의 사포닌 함량)/(원료의 사포닌 함량) * 100 (%)}로 계산하여, 68% 내지 84%의 추출효율을 확인하였다. 다만, 통상의 기술자는 본 발명의 사포닌 추출효율은 상기 수치에 제한되는 것이 아님을 이해할 것이다.In one embodiment of the present invention, the extraction efficiency was calculated as {(saponin content of ginseng extract) / (saponin content of raw material) * 100 (%)}, and 68% to 84% extraction efficiency was confirmed. However, it will be understood by a person skilled in the art that the saponin extraction efficiency of the present invention is not limited to the above values.
본 발명은 통상의 기술자가 당업계 공지된 다양한 방법에 의해 상기 인삼 추출물을 포함하는 인삼 가공 분말 조성물을 제공할 수 있다. 예컨대, 열풍건조, 냉풍건조, 또는 동결건조 등의 방법을 이용할 수 있으나, 이에 한정되는 것은 아니다.The present invention can provide a ginseng processed powder composition comprising the ginseng extract by a variety of methods known to those skilled in the art. For example, a method such as hot air drying, cold air drying, or freeze drying may be used, but the present invention is not limited thereto.
또한, 인삼 가공 분말 조성물의 제조방법에 있어, (b) 단계에서 상기 혼합물은 인삼 본연의 씁쓸한 맛을 감소시키고, 풍미를 증진시키기 위한 각종 감미제 및 기타 첨가제를 더 포함할 수 있다.In addition, in the method of manufacturing the ginseng processed powder composition, in the step (b), the mixture may further contain various sweeteners and other additives for reducing the bitter taste of ginseng and improving flavor.
상기 감미제는 예를 들어, 솔비톨, 올리고당, 벌꿀, 아카시아꿀, 락토스, 만니톨, 말티톨, 사카린, 수크랄로스, 설탕, 자일리톨, 타우린, 또는 이들의 혼합물을 사용할 수 있으나, 이에 한정되는 것은 아니다. 또한, 상기 감미제의 함량은 상등액 총 중량 대비 0.1 내지 20 중량% 포함할 수 있다. 상기 함량 내로 포함되는 경우, 조성물의 안정성을 저해하지 않는 범위 내에서, 향미를 증진시킬 수 있다.The sweetener may be, for example, sorbitol, oligosaccharide, honey, acacia honey, lactose, mannitol, maltitol, saccharin, sucralose, sugar, xylitol, taurine or a mixture thereof. The content of the sweetener may be 0.1 to 20% by weight based on the total weight of the supernatant. When contained in the above-mentioned content, the flavor can be enhanced within a range that does not impair the stability of the composition.
상기 기타 첨가제로는 예컨대, 필요에 따라 분말을 코팅하기 위한 코팅물질을 포함할 수 있다. 상기 코팅물질은 말토덱스트린, 전지분유, 탈지분유, 싸이클로덱스트린 등을 사용할 수 있으며, 바람직하게는 말토덱스트린 0.1 내지 15 중량%를 포함할 수 있다. 상기 함량 내로 포함되는 경우, 조성물의 안정성을 저해하지 않는 범위 내에서, 첨가제로서의 기능을 발휘할 수 있다.Such other additives may include, for example, a coating material for coating the powder as required. The coating material may be maltodextrin, whole milk powder, skim milk powder, cyclodextrin or the like, preferably 0.1 to 15% by weight of maltodextrin. When it is contained in the above-mentioned content, the function as an additive can be exhibited within a range that does not impair the stability of the composition.
특히, 본 발명은 통상적으로 당업계에 공지된 동결건조의 방법으로 하여 인삼 가공 분말 조성물을 제공할 수 있다.In particular, the present invention can provide a ginseng-processed powder composition with a freeze-drying method commonly known in the art.
일 실시예에서, 인삼 추출물을 건조하여 제조한 인삼 가공 분말 조성물을 유효성분으로 포함하여 유화액 제조 시, 인삼분말을 얻기 위해 수삼을 건조시킬 때, 건조온도가 낮을수록 유화처리 후 지방구의 입자크기가 변하지 않는 것을 확인하였다. 이를 통해, 인삼 추출물을 건조하여, 가공 분말 제조 시, 유화에 관여하는 성분이 열에 의해 변성될 수 있음을 확인하였고, 가공 분말 제조 시, 동결건조의 방법이 냉풍, 열풍건조의 방법보다 더 우수함을 확인하였다. 따라서, 인삼 추출물을 동결건조의 방법으로 분말화하는 경우, 유화안정성이 우수함을 확인하였다.In one embodiment, the ginseng powder composition prepared by drying the ginseng extract is used as an active ingredient. When the ginseng powder is dried to obtain the ginseng powder, the particle size of the fat sphere after emulsification is lower It was confirmed that it did not change. It was confirmed that the ingredients involved in emulsification could be denatured by heat when the ginseng extract was dried and the freeze drying method was better than the freezing method and the hot air drying method in preparing the processed powder Respectively. Therefore, it was confirmed that when the ginseng extract was powdered by the freeze drying method, the emulsion stability was excellent.
본 발명에 따른 가공방법에 따르면, 유화력 및 유화안정성이 개선된 인삼 가공 분말 조성물을 제공할 수 있다. 구체적으로 인삼 가공 분말 조성물을 물을 용매로 하여 0.2% 용액을 만들고, 620 nm 파장에서의 Optical Density(OD)를 측정하는 경우, OD 값이 0.1-0.4일 수 있으며; 사포닌의 함량은 건조된 인삼 가공 분말 조성물 기준 37-102 mg/g일 수 있으며; 단백질의 함량은 건조된 인삼 가공 분말 조성물 기준 9-13 중량%일 수 있으며; 또는 산당체의 함량은 건조된 인삼 가공 분말 조성물 기준 0.5-2.4 중량%일 수 있다.According to the processing method of the present invention, it is possible to provide a processed ginseng powder composition improved in emulsifying power and emulsion stability. Specifically, when a 0.2% solution is prepared using water as a solvent and the optical density (OD) at a wavelength of 620 nm is measured, the OD value may be 0.1-0.4; The content of saponin may be 37-102 mg / g based on dried ginseng processed powder composition; The protein content may be 9-13% by weight based on the dried ginseng processed powder composition; Or the content of the acid group may be 0.5-2.4 wt% based on the dried ginseng processed powder composition.
일 실시예에서, 본 발명의 인삼 가공 분말 조성물의 유화력을 확인하기 위하여, 인삼 가공 분말 조성물을 포함하는 용액을 제조하는 경우, 그 농도가 고농도일수록 계면장력값이 낮아지는 것을 확인하였다.In one embodiment, in order to confirm the emulsifying power of the ginseng processed powder composition of the present invention, it was confirmed that when the solution containing the ginseng processed powder composition was prepared, the interfacial tension value was lowered as the concentration was higher.
본 발명에 따른 명세서에 있어서 ‘계면장력’은 2종의 액체가 혼합하지 않고 층을 이루어 접할 때, 이 계면의 길이(또는 넓이)를 감소시키기 위해 발생하는 힘을 지칭하는 용어로, 그 값이 작아지는 경우 유화효과가 있음을 나타낸다. 통상적으로 mN/m의 단위로 측정할 수 있으며, 예컨대 KRUSS SITE 100 (KRUSS 사) 등의 계면장력측정기를 사용하여 측정될 수 있으나, 이에 제한되는 것은 아니다.In the specification of the present invention, the term "interfacial tension" refers to a force generated to reduce the length (or width) of the interface when the two kinds of liquids are layered without mixing, If it is small, it indicates that there is an emulsifying effect. Usually, it can be measured in units of mN / m and can be measured using an interfacial tension meter such as KRUSS SITE 100 (KRUSS), but is not limited thereto.
일 실시예에서, 본 발명자들은 인삼분말은 백삼분말을 사용하고, 용매로 에탄올을 사용하여 추출한 후, 동결건조하여 제조한 인삼 가공 분말 추출물을 물을 용매로 0.2% 용액, 0.01% 용액 및 0.0001% 용액을 제조하였다. 상기 용액들의 계면장력값을 측정한 결과, 0.2% 용액의 경우는 약 11 mN/m의 계면장력값을 갖고, 0.01% 용액의 경우 약 23 mN/m의 계면장력값을 갖고, 0.0001% 용액의 경우는 약 37 mN/m의 계면장력값을 얻었으며, 이를 통해, 인삼 가공 분말 조성물의 농도가 높을수록, 유화력이 좋아지는 것을 확인하였다.In one embodiment, the ginseng powder was prepared by dissolving ginseng powder in a solution of 0.2% solution, 0.01% solution and 0.0001% solution in water using white ginseng powder, extracting with ethanol as a solvent, and freeze- Solution. As a result of measuring the interfacial tension values of the solutions, the interfacial tension value of about 0.2 mN / m was found to be about 11 mN / m for the solution of 0.2%, the interfacial tension of about 0.01 mN / m for the solution of 0.01% , The interfacial tension value of about 37 mN / m was obtained. As a result, it was confirmed that the higher the concentration of the ginseng processed powder composition, the better the emulsifying power.
본 발명은 다른 종류의 인삼분말로부터 제조된 인삼 가공 분말 조성물을 혼합하여, 음료 조성물을 제공할 수 있다. 예컨대, 백삼 가공 분말 조성물과 홍삼 가공 분말 조성물을 혼합하여 음료 조성물을 제공할 수 있으며, 혼합하여 사용하는 경우, 혼합 중량비는 백삼분말:홍삼분말로 95:5 내지 60:40, 바람직하게는 90:10 내지 70:30, 가장 바람직하게는 80:20으로 혼합할 수 있다. 상기 혼합 중량비를 95:5 내지 60:40으로 하는 경우, 유화상태가 현저하게 개선된 음료 조성물을 제공할 수 있다.The present invention can provide a beverage composition by mixing ginseng processed powder compositions prepared from other kinds of ginseng powder. For example, the white ginseng processed powder composition and the red ginseng processed powder composition may be mixed to provide a beverage composition. When the mixture is used, the mixture weight ratio may be in the range of 95: 5 to 60:40, preferably 90: 10 to 70:30, and most preferably 80:20. When the mixing weight ratio is 95: 5 to 60:40, a beverage composition in which the emulsified state is remarkably improved can be provided.
일 실시예에서, 본 발명자들은 산당체 및 단백질 함량이 현저히 높은 백삼분말과 사포닌 함량이 현저히 높은 홍삼분말을 80:20으로 혼합하여 사용하는 경우, 인삼 추출물의 유화력과 유화안정성이 개선될 뿐만 아니라 사포닌 함량을 최대화 할 수 있음을 확인하였다.In one embodiment, when the white ginseng powder and the red ginseng powder having a significantly high content of saponin are mixed at a ratio of 80:20, the emulsifying power and emulsification stability of the ginseng extract are improved and the saponin It was confirmed that the content could be maximized.
본 발명은 본 발명에 따라 제조된 인삼 추출물을 포함하는 음료 조성물을 제공할 수 있다.The present invention can provide a beverage composition comprising the ginseng extract prepared according to the present invention.
본 발명에 따른 음료 조성물은 액제를 더 포함할 수 있으며, 이에 따라 액상 음료 조성물을 제공할 수 있다.The beverage composition according to the present invention may further comprise a liquid agent, thereby providing a liquid beverage composition.
상기 액제는 당 업계에서 액상 음료 조성물을 제조하기 위해 통상적으로 사용하는 액제이면 제한되지 않고 사용할 수 있다. 일 실시예에서, 본 발명자들은 본 발명에 따라 제조된 인삼 추출물을 증류수를 액제로 하여 음료 조성물을 제조하였다.The liquid agent can be used without limitation as long as it is a liquid agent conventionally used for producing a liquid beverage composition in the art. In one embodiment, the present inventors prepared a beverage composition using the ginseng extract prepared according to the present invention with distilled water as a liquid agent.
바람직하게는, 상기 액제의 함량은 인삼 추출물:액제 중량비 1:0.5-4로 포함할 수 있으며, 더 바람직하게는 1:1.5-3.5로 포함할 수 있다. 상기 액제의 함량이 인삼 추출물 대비 1:0.5-4인 경우 음료 조성물 총 중량 대비 인삼 첨가량이 2-5 중량%이며, 본 발명이 목적하는 사포닌을 다량 함유할 뿐만 아니라, 유화력 및 유화안정성이 개선된 액상 음료 조성물을 제공할 수 있다.Preferably, the content of the liquid agent may be 1: 0.5-4, and more preferably 1: 1.5-3.5. When the content of the liquid agent is 1: 0.5-4 relative to the ginseng extract, the added amount of ginseng is 2-5% by weight based on the total weight of the beverage composition, and the present invention not only contains a large amount of the desired saponin, A liquid beverage composition can be provided.
또한, 상기 음료 조성물은 인삼 본연의 씁쓸한 맛을 감소시키고, 풍미를 증진시키기 위한 각종 감미제 및 점증제를 더 포함할 수 있다.In addition, the beverage composition may further include various sweeteners and thickeners for reducing the bitter taste of ginseng and improving flavor.
상기 감미제는 예를 들어, 솔비톨, 올리고당, 벌꿀, 아카시아꿀, 락토스, 만니톨, 말티톨, 사카린, 수크랄로스, 설탕, 자일리톨, 타우린, 또는 이들의 혼합물을 사용할 수 있으나, 이에 한정되는 것은 아니다. 또한, 상기 감미제의 함량은 상등액 총 중량 대비 0.1 내지 20 중량% 포함할 수 있다.The sweetener may be, for example, sorbitol, oligosaccharide, honey, acacia honey, lactose, mannitol, maltitol, saccharin, sucralose, sugar, xylitol, taurine or a mixture thereof. The content of the sweetener may be 0.1 to 20% by weight based on the total weight of the supernatant.
상기 점증제는 필요에 따라 아라비아검, 구아검, 산탄검 등 각종 검의 혼합물 또는 통상적으로 음료 조성물에 사용하는 점증제를 사용할 수 있으며, 그 함량은 0.1 내지 5 중량%로 포함할 수 있다.The thickener may be a mixture of various gums such as gum arabic, guar gum, and xanthan gum or a thickening agent usually used in a beverage composition, if necessary, and the content thereof may be 0.1 to 5% by weight.
또한, 본 발명은 상기 인삼 가공 분말 조성물을 유화 유효성분으로 포함하는 음료 조성물을 제공할 수 있다.In addition, the present invention can provide a beverage composition comprising the ginseng processed powder composition as an emulsifying active ingredient.
일 실시예에서, 본 발명자들은 상기 인삼 가공 분말 조성물로 본 발명의 제조방법에 따라 제조된, 백삼 가공 분말 조성물을 사용하는 경우, 음료 조성물의 유화상태가 현저하게 개선되는 것을 확인하였다.In one embodiment, the inventors of the present invention confirmed that the emulsified state of the beverage composition was remarkably improved when the white ginseng processed powder composition prepared according to the manufacturing method of the present invention was used as the ginseng processed powder composition.
또한, 본 발명은 상기 인삼 추출물을 유화 유효성분으로 포함하는 인삼 유화 식품 조성물을 제공할 수 있으며, 특히 인삼 유화 음료 조성물을 제공할 수 있다.In addition, the present invention can provide a ginseng emulsified food composition containing the ginseng extract as an emulsifying active ingredient, and in particular, can provide a ginseng emulsified beverage composition.
또한, 본 발명에 따른 음료 조성물은 인삼 가공 분말 조성물 또는 인삼 추출물 외 별도의 유화제를 실질적으로 포함하지 않는다.In addition, the beverage composition according to the present invention does not substantially contain an emulsifier other than the ginseng processed powder composition or ginseng extract.
상기 ‘실질적으로 포함하지 않는다’는 조성물의 총 중량 대비 5 중량% 미만, 바람직하게 1 중량% 이하, 더욱 바람직하게 0.1 중량% 이하, 가장 바람직하게 0 중량% (즉, 전혀 포함하지 않음)로 포함하는 것을 의미한다.The 'substantially free' is included in an amount of less than 5 wt%, preferably less than 1 wt%, more preferably less than 0.1 wt%, and most preferably less than 0 wt% (i.e., not including at all) relative to the total weight of the composition .
따라서, 본 발명에 따른 인삼 가공 분말 조성물 또는 인삼 추출물을 유화 유효성분으로 포함하는 조성물은 다양한 분야에서 활용될 수 있다. 보다 구체적으로, 식품 조성물, 약학 조성물, 또는 화장품 조성물로 활용될 수 있다.Accordingly, the composition containing the ginseng processed powder composition or ginseng extract according to the present invention as an emulsifying active ingredient can be utilized in various fields. More specifically, it can be used as a food composition, a pharmaceutical composition, or a cosmetic composition.
본 발명은 사포닌 추출효율이 개선된 인삼 추출물 제조방법을 제공할 수 있으며, 또한 유화력 및 유화안정성이 개선된 인삼 추출물, 및 상기 인삼 추출물을 포함하는 조성물을 제공할 수 있으며, 특히 인삼 추출물 또는 인삼 가공 분말 조성물 외 별도의 유화제를 사용하지 않고 유화상태가 개선된 음료 조성물을 제공할 수 있다.The present invention can provide a ginseng extract having improved saponin extraction efficiency, a ginseng extract having improved emulsifying power and emulsion stability, and a composition containing the ginseng extract. In particular, a ginseng extract or a ginseng processed It is possible to provide a beverage composition in which the emulsified state is improved without using an emulsifier other than the powder composition.
도 1은 백삼분말을 일정량의 식용유지를 첨가한 물에 넣고 고속균질화 시키는 방법을 도시한 것이다.
도 2는 백삼분말과 홍삼분말의 첨가량을 달리하여 제조한 음료의 유화 상태를 도시한 것이다. 여기에서 백삼분말:홍삼분말의 혼합 중량비는 도면의 왼쪽부터 100:0, 70:30, 90:10, 92.5:7.5, 95:5, 97.5:2.5 이다.
도 3은 오일 첨가량에 따른 백삼분말, 홍삼분말 내 사포닌 추출함량을 진세노사이드 별로 나타내고 총 함량(total)을 나타낸 실험값이다. 사포닌 함량의 단위는 mg/g으로 나타내었다. 여기에서, No-1은 오일 농도에 따라 1차 유화처리, No-2는 1차 오일 유화처리 후 잔사를 다시 2차 오일 유화처리 한 것이며, No-Re는 2차오일로 유화처리 후 잔사에 대한 사포닌 함량을 나타낸다.
도 4는 오일 첨가량에 따른 홍삼분말 내 사포닌 추출함량을 진세노사이드 별로 나타내고 총 함량(total)을 나타낸 실험값이며, 사포닌 함량의 단위는 mg/ml이다. 여기에서, 식용유지는 카놀라유를 사용하였다.
도 5는 식용유지 첨가량에 따라 백삼분말, 홍삼분말 및 흑삼분말 내 사포닌 추출효율(%)을 비교하여 나타낸 것이다. 여기에서, 식용유지는 카놀라유를 사용하였다.
도 6은 인삼 추출물 제조 시 식용유지 첨가유무에 따른, 인삼 추출물을 포함하는 용액 제조 시, 유화상태를 비교한 사진이다.
도 7은 백삼분말, 홍삼분말, 및 흑삼분말 각각을 카놀라유를 5% 첨가한 물에 혼합한 후, 각각의 교반 속도에서 20분간 추출한 경우, 총 사포닌 함량을 비교하여 도시한 것이다. 여기에서, 원료는 원료의 총 사포닌 함량을 나타낸다.
도 8은 백삼분말, 홍삼분말, 및 흑삼분말 각각을 카놀라유를 5% 첨가한 물에 혼합한 후, 각각의 교반 시간 동안 10,000 rpm의 속도로 추출한 경우, 총 사포닌 함량을 비교하여 도시한 것이다. 여기에서, 원료는 원료의 총 사포닌 함량을 나타내며, 대조구는 각각의 분말을 메탄올에 용해한 후, 90-95°C에서 24시간 추출한 총 사포닌 함량 값을 나타낸다.
도 9는 본 발명의 방법에 따라 제조된 백삼 가공 분말 및 홍삼 가공 분말의 혼합비율에 따른 유화력 및 유화안정성을 비교한 그래프이다.
도 10은 본 발명의 방법에 따라 제조된 백삼 가공 분말 및 홍삼 가공 분말의 혼합비율에 따른 사포닌 추출 회수율을 비교한 그래프이다.
도 11은 인삼 추출물 제조 시, 식용유지의 종류별 유화안정성 및 기호도를 비교한 그래프이다.
도 12는 본 발명에 따라 인삼 추출물을 제조하는 제조방법의 기술공정도를 도시화한 것이다. 다만, 본 기술공정도는 바람직한 일 실시예에 불과할 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니다.
도 13은 본 발명에 따른 인삼 추출물을 포함하는 음료 조성물 및 분말 조성물을 제조하는 개발 공정도를 도시화한 것이다. 다만, 본 개발 공정도는 바람직한 일 실시예에 불과할 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니다.FIG. 1 shows a method of high-speed homogenization of white ginseng powder in water added with a certain amount of edible oil.
FIG. 2 shows the emulsified state of a beverage prepared by varying the addition amount of white ginseng powder and red ginseng powder. Here, the mixing weight ratio of white ginseng powder to red ginseng powder is 100: 0, 70:30, 90:10, 92.5: 7.5, 95: 5, and 97.5: 2.5 from the left side of the drawing.
FIG. 3 is an experimental value showing the total content (total) of ginseng powder extracted from white ginseng powder and red ginseng powder by ginsenosides according to the amount of oil added. The unit of saponin content is expressed in mg / g. Here, No-1 is the primary emulsification treatment according to the oil concentration, No-2 is the primary oil emulsification treatment and the residue is the secondary oil emulsion treatment. No-Re is the oil after the emulsification treatment with the secondary oil The content of saponin is shown.
FIG. 4 is an experimental value showing the total content (total) of ginsenosides extracted from red ginseng powder according to the amount of oil added, and the unit of saponin content is mg / ml. Here, canola oil was used as edible oil.
FIG. 5 shows the comparison of saponin extraction efficiency (%) in white ginseng powder, red ginseng powder and black ginseng powder according to the amount of edible oil added. Here, canola oil was used as edible oil.
FIG. 6 is a photograph showing the comparison of emulsified state when preparing a solution containing ginseng extract according to the presence or absence of edible oil in the production of ginseng extract.
FIG. 7 is a graph comparing total saponin contents when white ginseng powder, red ginseng powder, and black ginseng powder were mixed in water added with 5% canola oil and then extracted for 20 minutes at each stirring speed. Here, the raw material represents the total saponin content of the raw material.
8 is a graph comparing the total saponin contents when white ginseng powder, red ginseng powder, and black ginseng powder were mixed in water added with 5% canola oil and then extracted at a speed of 10,000 rpm for each agitation time. Here, the raw material represents the total saponin content of the raw material, and the control represents the total saponin content value obtained by dissolving each powder in methanol and then extracting it at 90-95 ° C for 24 hours.
9 is a graph comparing emulsification power and emulsion stability according to the mixing ratio of white ginseng powder and red ginseng powder prepared according to the method of the present invention.
10 is a graph comparing saponin extraction recovery rates according to mixing ratios of white ginseng powder and red ginseng powder prepared according to the method of the present invention.
FIG. 11 is a graph comparing emulsion stability and preference of each ginseng extract according to the kind of edible oil.
FIG. 12 is a graphical representation of the degree of the skilled artisan in the method of manufacturing ginseng extract according to the present invention. It should be noted, however, that the technical degree of the present invention is merely a preferred embodiment, and does not represent all of the technical ideas of the present invention.
FIG. 13 is a view illustrating a development process for preparing beverage compositions and powder compositions containing ginseng extract according to the present invention. However, the present development process diagram is merely a preferred embodiment, and does not represent all the technical ideas of the present invention.
이하, 본 발명을 도면 및 실시예 등을 참조하여 상세히 설명하기로 한다. 본 명세서에 기재된 실시예와 도면에 도시된 구성은 본 발명의 가장 바람직한 일 실시예에 불과할 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.Hereinafter, the present invention will be described in detail with reference to the drawings, examples and the like. It should be noted that the embodiments described in the present specification and the configurations shown in the drawings are only the most preferred embodiments of the present invention and are not intended to represent all of the technical ideas of the present invention so that various equivalents And variations are possible.
인삼분말 내 사포닌 추출함량 및 추출효율 비교Comparison of Saponin Extract Content and Extraction Efficiency in Ginseng Powder
식용유지의 함량에 따른 인삼분말 내 사포닌 추출함량을 비교하기 위하여, 인삼분말, 물, 식용유지를 혼합하여 4,000 rpm의 속도로 30분간 교반한 후, 상등액을 회수하여 사포닌 추출함량을 도 3-4에 나타내었다. 인삼분말은 백삼분말과 홍삼분말을 사용하였으며, No-1은 오일농도에 따라 1차 유화처리, No-2는 1차 오일 유화처리 후 잔사를 다시 2차 오일 유화처리 한 것이며, No-Re는 2차 오일로 유화처리 후 잔사에 대한 사포닌 함량을 나타낸다.The ginseng powder, water, and edible oil were mixed and stirred at a speed of 4,000 rpm for 30 minutes in order to compare the content of saponin extract in the ginseng powder according to the content of edible oil. Respectively. Ginseng powder was white ginseng powder and red ginseng powder. No-1 was the first emulsion treatment according to the oil concentration, No-2 was the first oil emulsion treatment, and the residue was again the second oil emulsion treatment. The saponin content of the residue after emulsification with secondary oil is shown.
또한, 식용유지의 함량에 따른 인삼분말 내 사포닌 추출효율을 비교하기 위하여, 상기의 사포닌 추출함량에 대한 사포닌 추출효율을 도 5에 나타내었다. 흑삼분말에 대하여도 위와 같이 사포닌을 추출하여 함량을 측정하였으며, 식용유지는 카놀라유를 사용하였다. 추출효율은 ‘추출물 내 사포닌 함량/가공 전 사포닌 함량 * 100 (%)’으로 계산되었다.In addition, in order to compare saponin extraction efficiency with ginseng powder according to the content of edible oil, the saponin extraction efficiency with respect to the saponin extract content is shown in FIG. As for the black ginseng powder, the content of the saponin was extracted and measured, and canola oil was used as the edible oil. The extraction efficiency was calculated as 'saponin content in extract / saponin content * 100 (%)' before processing.
도 3 및 4에서 보는 바와 같이, 오일 첨가량이 증가할수록, 인삼분말 내 사포닌 추출 함량이 증가하는 경향을 나타내었다.As shown in FIGS. 3 and 4, the saponin extract content of the ginseng powder tended to increase as the amount of oil added increased.
도 5에서 보는 바와 같이, 홍삼 특유 사포닌은 식용유지 첨가량이 높을수록 추출효율이 증가하는 것을 확인하였다.As shown in FIG. 5, it was confirmed that the extraction efficiency of red ginseng-specific saponin was increased as the amount of edible oil added was higher.
실시예 1-3 및 비교예 1-4의 사포닌 추출함량 비교Comparison of Saponin Extraction Contents of Examples 1-3 and Comparative 1-4
백삼분말을 카놀라유를 5% 혼합한 물에 넣고 속도 10,000 rpm으로 각각 20분, 40분, 60분 동안 교반한 후, 상등액을 회수하여 사포닌 추출함량을 표 1에 나타내었다. 사포닌 함량은 건물 기준 mg/g으로 표시되었다.The white ginseng powder was added to water mixed with 5% canola oil and stirred at a speed of 10,000 rpm for 20 minutes, 40 minutes and 60 minutes, respectively. The supernatant was recovered and the saponin extract content was shown in Table 1. The saponin content was expressed in mg / g of the building standard.
실시예 1-3은 각각 20분, 40분, 60분의 교반과정을 거쳐 제조되었다.Example 1-3 was prepared by stirring for 20 minutes, 40 minutes, and 60 minutes, respectively.
비교예 1은 백삼분말을 70% 메탄올과 혼합한 후 50°C에서 5시간 동안 추출한 후 사포닌 추출함량을 나타낸 것이다.In Comparative Example 1, white ginseng powder was mixed with 70% methanol and extracted at 50 ° C for 5 hours.
비교예 2-4는 식용유지를 혼합하지 않은 물에 백삼분말을 넣고 속도 10,000 rpm으로 각각 20분, 40분, 60분 동안 교반한 후, 사포닌 추출함량을 나타낸 것이다.In Comparative Example 2-4, white ginseng powder was added to water not mixed with edible oil and stirred at a rate of 10,000 rpm for 20 minutes, 40 minutes, and 60 minutes, respectively.
물 단독의 용매를 이용하여 인삼 추출물을 제조한 비교예 2-4가 사포닌 함량이 18.39-20.37 mg/g인 점과 비교하여, 식용유지를 혼합한 용매를 이용하여 인삼 추출물을 제조한 실시예 1-3의 사포닌 함량이 20.54-25.48 mg/g으로 식용유지를 혼합하여 추출한 경우, 사포닌 추출에 있어 더 우수함을 확인하였다.Comparative Example 2-4, in which a ginseng extract was prepared using a water-only solvent, was compared with that in which the saponin content was 18.39-20.37 mg / g. In Example 1- 3 saponin was 20.54-25.48 mg / g, which is superior to saponin extraction.
또한, 사포닌 총 함량에 있어 비교예 1이 29.63 mg/g으로 실시예 1-3과 비교하여 더 높았으나, 시간당 추출함량으로 환산하여 비교하면, 추출시간이 5시간이었던 비교예 1은 29.63mg/g /5hr로 계산하여, 5.93 mg/g·hr인데 반해, 추출시간이 1시간이었던 실시예 3은 25.48 mg/g·hr로, 실시예가 추출효율의 측면에서 비교예 1보다 더 우수함을 확인하였다.Also, the total content of saponin was 29.63 mg / g in Comparative Example 1, which was higher than that in Example 1-3. However, Comparative Example 1 in which the extraction time was 5 hours was 29.63 mg / g / hr and 5.93 mg / g · hr, respectively. In Example 3, which was 1 hour of extraction time, it was 25.48 mg / g · hr, which is superior to Comparative Example 1 in terms of extraction efficiency .
추출조건의 비교: 교반 속도 및 추출시간Comparison of extraction conditions: stirring speed and extraction time
백삼분말, 홍삼분말, 및 흑삼분말 각각을 카놀라유를 혼합한 메탄올에 용해한 후, 각각의 추출조건에 따라 추출한 총 사포닌 함량 값을 도 7-8에 나타냈다. 특히, 동일 시간동안 교반 속도를 달리한 결과를 도 7에 나타냈으며, 동일 교반 속도에서 추출시간을 달리한 결과를 도 8에 나타내었다.The total saponin content of each of the white ginseng powder, red ginseng powder, and black ginseng powder was dissolved in methanol mixed with canola oil and extracted according to the respective extraction conditions, as shown in Figs. 7-8. In particular, the results of varying the stirring speed for the same time are shown in FIG. 7, and the results of varying the extraction time at the same stirring speed are shown in FIG.
원료는 식품공전에 표기된 인삼사포닌 분석방법에 따라 묽은 메탄올로 50~60℃의 온도에서 추출하여 총 사포닌 함량이 측정되었으며, 대조구는 각각의 분말을 물에 용해한 후, 90-95°C에서 24시간 추출하였다.The total saponin content of the raw materials was measured at 50 ~ 60 ℃ using diluted methanol according to the ginseng saponin analysis method described in the Food Code. The control was performed by dissolving each powder in water and incubating at 90-95 ° C for 24 hours And extracted.
도 7은 20분 동안 교반 속도를 달리하여 측정한 결과로, 추출 단계에서 교반 속도를 높일수록, 총 사포닌 함량이 증가하는 것을 확인하였다.FIG. 7 shows that the total saponin content was increased as the stirring speed was increased in the extraction step, as a result of measuring the stirring speed for 20 minutes.
도 8은 10,000 rpm의 속도로 추출시간을 달리하여 측정한 결과로, 추출 단계에서 추출시간을 늘릴수록, 총 사포닌 함량이 증가하는 것을 확인하였다. 또한, 90-95°C에서 24시간 추출한 대조구와 비교하여, 추출시간이 20분 이상인 경우, 본 발명의 방법에 따라 제조된 인삼 추출물 내 총 사포닌 함량이 개선되는 것을 확인하였다.FIG. 8 shows that the total saponin content increases as the extraction time is increased in the extraction step, as a result of measurement at a different extraction time at a rate of 10,000 rpm. In addition, it was confirmed that the total saponin content in the ginseng extract prepared according to the method of the present invention was improved when the extraction time was 20 minutes or longer as compared with the control which was extracted for 24 hours at 90-95 ° C.
실시예Example 4-7의 제조 및 유화상태 비교 Manufacturing and emulsifying status of 4-7
[실시예 4-7의 제조][Preparation of Example 4-7]
인삼분말, 물, 식용유지(카놀라유)를 사용하여, 본 발명의 제조방법에 따라 인삼 가공 분말 조성물 실시예 4-7을 제조하였다. 실시예 4는 인삼분말로 백삼분말을 사용하였고, 용매로 물을 사용하여 제조하였으며, 실시예 5는 인삼분말로 백삼분말을 사용하였고, 용매로 70% 에탄올을 사용하여 제조하였으며, 실시예 6은 인삼분말로 흑삼분말을 사용하였고, 용매로 물을 사용하여 제조하였으며, 실시예 7은 인삼분말로 흑삼분말을 사용하였고, 용매로 70% 에탄올을 사용하여 제조하였다.Using ginseng powder, water and edible oil (canola oil), ginseng processed powder composition Example 4-7 was prepared according to the preparation method of the present invention. In Example 4, white ginseng powder was used as a ginseng powder and water was used as a solvent. In Example 5, white ginseng powder was used as a ginseng powder and 70% ethanol was used as a solvent. In Example 6, The ginseng powder was prepared by using black ginseng powder and water as a solvent. Example 7 was prepared by using ginseng powder as black ginseng powder and 70% ethanol as a solvent.
[계면장력값 측정][Measurement of interfacial tension value]
제조한 실시예 4-7을 농도를 달리하여 희석한 후, 각각에 대한 계면장력값을 표 2에 나타내었다.Table 4 shows the interfacial tension values for each of Examples 4-7 prepared after dilution with different concentrations.
[OD 측정][OD measurement]
제조한 실시예 4-7, 및 시판 유화제인 Span 20, Tween 20, Tween 40, Tween 60의 620 nm에서의 Optical Density를 측정하여 표 3에 나타내었다. 제조한 실시예 4-7 및 시판 유화제는 0.2% 농도가 되도록 물에 희석하여 측정하였다.Optical Density at 620 nm of
(620nm)OD
(620 nm)
[인삼 유효성분의 함량 측정][Determination of content of active ingredients of ginseng]
제조한 실시예 4-7 내 사포닌, 단백질, 산당체 함량을 표 4에 나타내었다. 사포닌 함량은 실시예 4-7의 건조 분말 기준으로 mg/g으로 측정되었으며, 단백질, 산당체 함량은 분말 조성물 총 중량 대비 중량%로 측정되었다.Saponin, protein, and acid sugar content of the prepared Example 4-7 are shown in Table 4. The saponin content was measured in mg / g on the basis of the dry powder of Example 4-7, and the protein and acid sugar content were measured in terms of% by weight based on the total weight of the powder composition.
[유화력 비교 결과][Comparison result of emulsifying power]
표 2를 통해, 0.00001% 농도에서는 각 용액의 계면장력값이 비슷하나, 고농도로 갈수록 계면장력값이 작아지는 것을 통해, 실시예 4-7이 유화력이 있음을 확인하였다. 그 중에서도, 실시예 6 및 실시예 7의 경우가 계면장력값이 작았으며, 이에 따라 유화효과는 실시예 6-7의 경우가 우수함을 확인하였다.The results are shown in Table 2. As shown in Table 2, the interfacial tension values of the respective solutions at the concentration of 0.00001% are similar, but the interfacial tension values become smaller toward the higher concentration. Among them, in Examples 6 and 7, the interfacial tension value was small, and thus it was confirmed that the emulsification effect was excellent in the case of Example 6-7.
그러나, 표 3을 통해 실시예 4의 OD값은 시판 유화제인 Tween20 및 Tween40 보다 큰 값을 나타냈고, 실시예 4-7 중 실시예 4의 OD값이 가장 큰 것을 확인할 수 있었다. 이에 따라 실시예 4의 유화상태가 가장 우수함을 확인하였다.However, in Table 3, the OD value of Example 4 was larger than that of
표 4의 사포닌 함량을 비교하는 경우, 실시예 6-7의 사포닌 함량이 각각 69.70 mg/g, 101.52 mg/g으로 실시예 4(37.96 mg/g) 및 실시예 5(51.69 mg/g)보다 높았으며, 이는 표 2의 실시예 6-7의 계면장력값이 낮은 결과와 상응하였다. 이를 통해, 사포닌의 함량이 높을수록 유화력이 우수함을 확인하였다.When the saponin contents in Table 4 were compared, the saponin contents in Examples 6-7 were 69.70 mg / g and 101.52 mg / g, respectively, and that of Example 4 (37.96 mg / g) and Example 5 (51.69 mg / g) , Which corresponded to the low interfacial tension values of Examples 6-7 in Table 2. < tb > < TABLE > From these results, it was confirmed that the higher the saponin content, the better the emulsifying power.
한편, 표 4의 사포닌 외 성분, 즉 단백질 및 산당체 함량을 비교하는 경우, 실시예 4의 경우가 단백질 및 산당체 함량이 총 15.06±0.2으로, 가장 높은 것을 확인하였으며, 이는 표 3의 OD 측정을 통해 확인하였듯이, 유화상태가 가장 우수한 것과 상응하였다. 이를 통해, 유화상태는 사포닌 이외에 단백질 및 산당체가 관여함을 확인하였다.On the other hand, in the case of comparing the external components of saponin in Table 4, that is, the protein and the acid carbohydrate content, it was confirmed that the content of protein and acid in the case of Example 4 was the highest of 15.06 ± 0.2, , The emulsified state corresponds to the best one. As a result, it was confirmed that the emulsified state was involved in the protein and the acidic body in addition to the saponin.
종합하면, 유화상태는 유화력과 유화안정성에 의해 평가될 수 있으며, 사포닌의 함량이 높을수록 유화력이 개선되며, 사포닌 외 단백질 및 산당체의 함량이 높을수록 유화안정성이 개선되는 것을 확인하였다.In summary, the emulsified state can be evaluated by emulsifying power and emulsion stability, and the emulsifying power is improved as the content of saponin is higher, and the emulsification stability is improved as the content of saponin and protein and acid sugar is higher.
결론적으로, 사포닌 함량이 높은 실시예 7과 단백질 및 산당체 함량이 높은 실시예 4를 적절히 혼합하여 유화액을 제조하는 경우, 유화상태가 가장 개선될 수 있음을 확인하였다.In conclusion, it was confirmed that the emulsified state can be most improved when Example 7 having a high saponin content and Example 4 having a high protein and acid saccharide content are appropriately mixed to prepare an emulsion.
혼합분말의 혼합비에 따른 유화상태 비교Comparison of emulsified state according to mixing ratio of mixed powders
삼 가공 분말 조성물 및 홍삼 가공 분말 조성물의 혼합비에 따른 유화력 및 유화안정성을 비교하기 위해, 백삼 가공 분말:홍삼 가공 분말의 혼합 중량비가 100:0 내지 0:100이 되도록 분말을 혼합하였다. 그 후, 분말 총 중량의 10배 중량의 물, 물 총 중량의 5 중량%의 카놀라유, 상기 혼합한 분말을 모두 혼합한 후, 10,000 rpm 으로 40분 동안 교반하였다.In order to compare the emulsifying power and emulsification stability according to the mixing ratio of the three processed powder compositions and the red ginseng processed powder composition, the powders were mixed such that the mixing ratio of the white ginseng powder to the red ginseng powder was 100: 0 to 0: 100. Then, 10 times by weight of the total weight of the powder, 5% by weight of the total weight of canola oil, and the mixed powder were mixed and stirred at 10,000 rpm for 40 minutes.
40분의 교반이 끝난 후, 620 nm에서의 OD 값을 측정하여 유화력을 비교하였으며, 유화액 내 미세지방구의 평균 크기로 유화안정성을 비교하여 그 결과를 도 9에 나타내었다. After stirring for 40 minutes, OD value at 620 nm was measured to compare the emulsifying powers. The emulsion stability was compared with the average size of the micro-lipids in the emulsion, and the results are shown in FIG.
또한, ‘추출물 내 사포닌 함량/원물 내 사포닌 함량 * 100 (%)’의 방법으로 사포닌 추출회수율을 계산하여, 각 혼합비율에 따른 사포닌추출회수율을 도 11에 나타내었다.Saponin extraction recovery rate was calculated by the method of 'saponin content in extract / saponin content in raw material * 100 (%)', and the saponin extraction recovery rate according to each mixing ratio is shown in FIG.
도 9에서 볼 수 있듯이, 백삼 가공 분말: 홍삼 가공 분말의 혼합비가 80:20-40:60인 경우, 유화액 내 유화력 및 유화안정성 측면에서 우수함을 확인하였다.As can be seen from FIG. 9, when the mixing ratio of the white ginseng powder: red ginseng powder was 80: 20-40: 60, it was confirmed that the emulsifying power and the emulsion stability in the emulsion were excellent.
도 10에서 볼 수 있듯이, 백삼 가공 분말: 홍삼 가공 분말의 혼합비가 95:5-80:20인 경우, 사포닌의 함량이 우수함을 확인하였다.As shown in FIG. 10, when the mixing ratio of white ginseng powder: red ginseng powder was 95: 5-80: 20, it was confirmed that the content of saponin was excellent.
이를 통해 인삼 가공 분말을 혼합하여, 조성물 내 유화 유효성분으로 사용하는 경우 ,그 혼합비가 80:20일 때 유화상태가 개선된 조성물을 제조할 수 있을 뿐만 아니라, 사포닌 함량이 우수한 조성물을 제조할 수 있음을 확인하였다.When the ginseng processed powder is used as an effective component for emulsification in the composition, it is possible to prepare a composition having an improved emulsified state when the mixing ratio thereof is 80:20, as well as a composition having excellent saponin content Respectively.
Claims (18)
A ginseng extract which is prepared by mixing edible oil with an extraction solvent.
(b) 상기 혼합물을 이용해 추출물을 제조하는 단계를 포함하는 인삼 추출물 제조방법.(a) mixing ginseng powder, a solvent, and an edible oil; And
(b) preparing an extract using the mixture.
상기 혼합분말 내 혼합 중량비는 백삼분말:홍삼분말로 95:5 내지 60:40인 것을 특징으로 하는 인삼 추출물 제조방법.[Claim 3] The method according to claim 2, wherein the ginseng powder in (a) is a mixed powder of white ginseng powder and red ginseng powder,
Wherein the mixing weight ratio of the ginseng powder to the ginseng powder is from 95: 5 to 60:40 as white ginseng powder: red ginseng powder.
(c) 상기 고속 균질화 후 상등액을 회수하는 단계를 더 포함하며; 및
상기 고속 균질화는
(b1) 5,000 내지 10,000 rpm인 일정한 속도에서 5 내지 40분 동안 교반하는 제 1 균질단계;
(b2) 10,000 내지 15,000 rpm인 일정한 속도에서 5 내지 100분 동안 교반하는 제 2 균질단계를 포함하는 것을 특징으로 하는 인삼 추출물 제조방법.3. The method of claim 2, wherein (b) is a high-speed homogenization step;
(c) recovering the supernatant after the high-speed homogenization; And
The high-speed homogenization
(b1) a first homogenizing step at a constant speed of 5,000 to 10,000 rpm for 5 to 40 minutes;
(b2) a second homogenization step at a constant speed of 10,000 to 15,000 rpm for 5 to 100 minutes.
(d) 인삼 추출물을 농축하는 단계를 더 포함하여, 고농축 인삼 추출물을 제조하는 것을 특징으로 하는 인삼 추출물 제조방법.[Claim 3] The method according to claim 2,
(d) concentrating the ginseng extract to produce a highly concentrated ginseng extract.
상기 액제의 함량은 인삼 추출물:액제 중량비 1:0.5-4인 것을 특징으로 하는 음료 조성물.14. The beverage composition of claim 13, wherein the beverage composition further comprises a liquid agent,
Wherein the content of the liquid agent is 1: 0.5-4 in weight ratio of ginseng extract: liquid.
상기 감미제의 함량은 조성물 총 중량 대비 0.1 내지 20 중량%인 것을 특징으로 하는 음료 조성물.14. The beverage composition of claim 13, further comprising a sweetener;
Wherein the content of the sweetener is 0.1 to 20% by weight based on the total weight of the composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170028354A KR101924280B1 (en) | 2017-03-06 | 2017-03-06 | Composition comprising ginseng extract and method for preparation of ginseng extract with enhanced saponine extraction efficiency and composition comprising ginseng extract thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170028354A KR101924280B1 (en) | 2017-03-06 | 2017-03-06 | Composition comprising ginseng extract and method for preparation of ginseng extract with enhanced saponine extraction efficiency and composition comprising ginseng extract thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180101861A true KR20180101861A (en) | 2018-09-14 |
KR101924280B1 KR101924280B1 (en) | 2019-02-22 |
Family
ID=63599543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170028354A KR101924280B1 (en) | 2017-03-06 | 2017-03-06 | Composition comprising ginseng extract and method for preparation of ginseng extract with enhanced saponine extraction efficiency and composition comprising ginseng extract thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101924280B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210048138A (en) * | 2019-10-23 | 2021-05-03 | 주식회사 한국인삼공사 | Method for Preparing Pills Comprising Ginseng |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100211718B1 (en) * | 1997-04-04 | 1999-08-02 | 박명규 | A processing for preparing an anabolic ginseng and its products |
KR100599395B1 (en) * | 2004-03-22 | 2006-07-12 | 주식회사농심 | Ginseng Drinks and The Process for The Same |
KR100658772B1 (en) | 2004-01-20 | 2006-12-15 | 씨제이 주식회사 | A drink containing ultrafine powder of ginseng and the method thereof |
JP2007254343A (en) * | 2006-03-23 | 2007-10-04 | Naris Cosmetics Co Ltd | Cosmetic containing carrot extract |
KR20100109706A (en) * | 2009-04-01 | 2010-10-11 | 주식회사 엔에이치한삼인 | A preparation method of ginseng extracts for maximal utilization of lipid soluble and water soluble bioactive components in ginseng |
-
2017
- 2017-03-06 KR KR1020170028354A patent/KR101924280B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100211718B1 (en) * | 1997-04-04 | 1999-08-02 | 박명규 | A processing for preparing an anabolic ginseng and its products |
KR100658772B1 (en) | 2004-01-20 | 2006-12-15 | 씨제이 주식회사 | A drink containing ultrafine powder of ginseng and the method thereof |
KR100599395B1 (en) * | 2004-03-22 | 2006-07-12 | 주식회사농심 | Ginseng Drinks and The Process for The Same |
JP2007254343A (en) * | 2006-03-23 | 2007-10-04 | Naris Cosmetics Co Ltd | Cosmetic containing carrot extract |
KR20100109706A (en) * | 2009-04-01 | 2010-10-11 | 주식회사 엔에이치한삼인 | A preparation method of ginseng extracts for maximal utilization of lipid soluble and water soluble bioactive components in ginseng |
Non-Patent Citations (1)
Title |
---|
高麗人蔘, 1994, 韓國人蔘煙草硏究院 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210048138A (en) * | 2019-10-23 | 2021-05-03 | 주식회사 한국인삼공사 | Method for Preparing Pills Comprising Ginseng |
Also Published As
Publication number | Publication date |
---|---|
KR101924280B1 (en) | 2019-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2854828B1 (en) | A method of preparing a panax spp. plant extract with increased content ratio of ginsenoside rg3, rg5, and rk1 produced by microwave irradiation | |
CN102763752B (en) | Instant functional maca coffee and production method thereof | |
CN103747794A (en) | Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis | |
KR102020586B1 (en) | Healthy foods for elderly comprising animal and plant extracts and process for preparation thereof | |
KR101429820B1 (en) | Extract of ginseng seed, composition or oil having the same, and preparing method thereof | |
CN106165896A (en) | A kind of manufacture method of Maca extract | |
WO2007133054A1 (en) | A novel process for preparing black ginseng and the composition comprising the same | |
CN102329715A (en) | Compound Rhodiola rosea wine and preparation method thereof | |
KR101075067B1 (en) | Solid food process using acer mono max liquid and mountaingrown ginseng | |
CN105996028A (en) | Ginger extract, ginger fiber and preparation method of ginger extract and ginger fiber | |
KR20170061327A (en) | Anti-obesity compositions and methods of manufacturing the same as a main component of raspberry leaf and stem extract | |
WO2008075866A1 (en) | A composition comprising the processed extract of panax quinquefolium l. for the prevention and treatment of cancer | |
KR101924280B1 (en) | Composition comprising ginseng extract and method for preparation of ginseng extract with enhanced saponine extraction efficiency and composition comprising ginseng extract thereof | |
CN106109584A (en) | The extraction process of Fructus psidii guajavae immaturus active substance and application thereof | |
CN105795292A (en) | Drink containing corn stigma and ginseng and preparation method of drink | |
JP6444440B2 (en) | Method for producing akebi extract and functional food using the extract | |
KR101435930B1 (en) | Method for production of red ginseng extract enhancing ginsenoside Rg3 and use of thereof as ginsenoside Rg3 enriched products | |
KR101419037B1 (en) | Manufacturing method of friut icecream containing soft persimmon and yellow pumpkin | |
KR102043433B1 (en) | Method for Making Extract of Red Ginseng | |
CN106074655A (en) | Nanoscale Eurycoma longifolia and the preparation method of Maca mixed extract | |
CN106581166A (en) | Anti-fatigue food, health product or pharmaceutical composition | |
CN103815080B (en) | Tartary buckwheat instant tea and preparation method thereof | |
CN105039112A (en) | Maca life-nourishing and health-care liquor and making method thereof | |
KR20160134375A (en) | Water soluble composition comprising ginseng seed oil | |
CN107348278A (en) | A kind of corn soda water and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |